Substituting Warfarin Products: What's the Source of the Problem?

Annals of Pharmacotherapy

Volumn 45, Issue 6, 2011, Pages 807-809

  Haines, Stuart T ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Anticoagulation therapy; Generic substitution; Warfarin

Indexed keywords

WARFARIN;

ANTICOAGULATION; ARTICLE; BIOEQUIVALENCE; BLEEDING; DRUG BIOAVAILABILITY; DRUG SUBSTITUTION; HUMAN; LITERATURE; PRIORITY JOURNAL; STANDARDIZATION; THROMBOEMBOLISM;

ANTICOAGULANTS; DRUGS, GENERIC; HEMORRHAGE; HUMANS; THERAPEUTIC EQUIVALENCY; THROMBOEMBOLISM; WARFARIN;

EID: 79958810663     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q063     Document Type: Article

References (21)

1. Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. Can J Clin Pharmacol 2005;12:e229-39.
2. Bongiorno RA, Nutescu EA. Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers. Semin Thromb Hemost 2004;30:619-26. DOI 10.1055/s-2004-861503
3. Benson SR, Vance-Bryan K. In favor of Coumadin over generic warfarin. Am J Health Syst Pharm 1998;55:727-9.
4. Wittkowsky AK. Generic warfarin: implications for patient care. Pharmacotherapy 1997;17:640-3.
5. Milligan PE, Banet GA, Waterman AD, Gatchel SK, Gage BF. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002;36:764-8. DOI 10.1345/aph.1A327.
6. Witt DM, Tillman DJ, Evans CM, Plotkin TV, Sadler MA. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 2003;23:360-8. DOI 10.1592/phco.23.3.360.32103
7. Lawrence J. State by state, DuPont Merck battles to limit NTI substitution. Drug Store News January 12, 1998. http://findarticles.com/p/articles/mi_m3374/is_n1_v20/ai_20801949/(accessed 2011 Mar 2).
8. Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-8.
9. Meibohm B, Zhang W, Beierle I, Meyer MC. Epistaxis associated with levation of INR in a patient switched to generic warfarin-another view. Pharmacotherapy 2000;20:866-9. DOI 10.1592/phco.20.9.866.35190
10. Wagner JL, Dent LA. Epistaxis associated with elevation of INR in a patient switched to generic warfarin. Pharmacotherapy 2000;20:240-3. DOI 10.1592/phco.20.3.240.34784
11. Hope KA, Havrda DE. Subtherapeutic INR values associated with a switch to generic warfarin. Ann Pharmacother 2001;35:183-7. DOI 10.1345/aph.10207
12. Haines ST. Reflections on generic warfarin. Am J Health Syst Pharm 1998;55:729-33.
13. Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization. Am J Health Syst Pharm 2000;57:452-5.
14. Paterson JM, Mamdani M, Juurlink DN, Naglie G, Laupacis A, Stukel TA. Clinical consequences of generic warfarin substitution: an ecological study. JAMA 2006;296:1969-72. DOI 10.1001/jama.296.16.1969-b
15. Lee HL, Kan CD, Yang YJ. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study. Clin Ther 2005;27:309-19. DOI 10.1016/j.clinthera.2005.03.004
16. Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann Pharmacother 2005;39:1188-93. DOI 10.1345/aph.1G003
17. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26. DOI 10.1001/jama.2008.758
18. Weibert RT, Yeager BF, Wittkowsky AK, et al. A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation. Ann Pharmacother 2000;34:981-8. DOI 10.1345/aph.10068
19. Handler J, Nguyen TT, Rush S, Pham NT. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prev Cardiol 1998;1:13-20.
20. Neutel JM, Smith DH. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep 1998;19:49-59.
21. Ghate SR, Biskupiak JE, Ye X, Hagan M. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with diagnosis of atrial fibrillation. A retrospective analysis. Ann Pharmacother 2011;45:701-12. DOI 10.1345/aph.1P593.